These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 19592450)

  • 1. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New drugs and targeted therapeutic agents in ovarian cancer].
    de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
    Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising molecular targets in ovarian cancer.
    Blagden S; Gabra H
    Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of targeted therapy in ovarian cancer.
    Banerjee S; Kaye S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted trials in ovarian cancer.
    Ledermann JA; Raja FA
    Gynecol Oncol; 2010 Oct; 119(1):151-6. PubMed ID: 20591473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies in breast cancer: where are we now?
    Di Cosimo S; Baselga J
    Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.
    Ziebarth AJ; Landen CN; Alvarez RD
    Clin Obstet Gynecol; 2012 Mar; 55(1):156-72. PubMed ID: 22343235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
    Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
    Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New biologic agents for the treatment of gynecologic cancers.
    Horowitz N; Matulonis UA
    Hematol Oncol Clin North Am; 2012 Feb; 26(1):133-56. PubMed ID: 22244666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting angiogenesis in ovarian cancer.
    Schmitt J; Matei D
    Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
    Willmott LJ; Monk BJ
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):895-903. PubMed ID: 19589029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis: a promising therapeutic target for ovarian cancer.
    Bamias A; Pignata S; Pujade-Lauraine E
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other new targets.
    Mackay HJ; Oza AM
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S49-54. PubMed ID: 19955915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
    Isayeva T; Ren C; Ponnazhagan S
    Gene Ther; 2007 Jan; 14(2):138-46. PubMed ID: 16943851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
    Markman M
    Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
    Martin L; Schilder R
    J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.